KR102882868B1 - 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도 - Google Patents

화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도

Info

Publication number
KR102882868B1
KR102882868B1 KR1020197026718A KR20197026718A KR102882868B1 KR 102882868 B1 KR102882868 B1 KR 102882868B1 KR 1020197026718 A KR1020197026718 A KR 1020197026718A KR 20197026718 A KR20197026718 A KR 20197026718A KR 102882868 B1 KR102882868 B1 KR 102882868B1
Authority
KR
South Korea
Prior art keywords
isolamide
compounds
extract
preparing
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197026718A
Other languages
English (en)
Korean (ko)
Other versions
KR20190121790A (ko
Inventor
크리스티아노 루크 베르넥 구이마라에스
카를로스 에두아르도 비토르
리산드라 라바넬리 페싸
로물로 드라가니 레이스
알레산드라 마스카렐로
페르난도 엔리케 데 소우자 가마
Original Assignee
아체 라보라토리오스 파마슈티코스 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아체 라보라토리오스 파마슈티코스 에스.에이. filed Critical 아체 라보라토리오스 파마슈티코스 에스.에이.
Priority to KR1020257031344A priority Critical patent/KR20250145126A/ko
Publication of KR20190121790A publication Critical patent/KR20190121790A/ko
Application granted granted Critical
Publication of KR102882868B1 publication Critical patent/KR102882868B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
KR1020197026718A 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도 Active KR102882868B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257031344A KR20250145126A (ko) 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
BRBR1020170033180 2017-02-17
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257031344A Division KR20250145126A (ko) 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도

Publications (2)

Publication Number Publication Date
KR20190121790A KR20190121790A (ko) 2019-10-28
KR102882868B1 true KR102882868B1 (ko) 2025-11-07

Family

ID=61282932

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197026718A Active KR102882868B1 (ko) 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도
KR1020257031344A Pending KR20250145126A (ko) 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257031344A Pending KR20250145126A (ko) 2017-02-17 2018-02-19 화합물, 화합물의 제조 방법, 강화된 추출물, 강화된 추출물 활성 분획, 강화된 추출물의 제조 방법, 강화된 추출물 제조를 위한 식물성 바이오매스의 선택 방법, 면역학적 장애의 치료를 위한 조성물 및 용도

Country Status (28)

Country Link
US (1) US12698265B2 (cg-RX-API-DMAC7.html)
EP (2) EP3583103B1 (cg-RX-API-DMAC7.html)
JP (2) JP7349362B2 (cg-RX-API-DMAC7.html)
KR (2) KR102882868B1 (cg-RX-API-DMAC7.html)
CN (1) CN110475768B (cg-RX-API-DMAC7.html)
AU (2) AU2018221956B2 (cg-RX-API-DMAC7.html)
BR (1) BR102017003318A2 (cg-RX-API-DMAC7.html)
CA (2) CA3052713A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019008891A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125187T1 (cg-RX-API-DMAC7.html)
DK (1) DK3583103T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP19058322A (cg-RX-API-DMAC7.html)
ES (1) ES2909387T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220377T1 (cg-RX-API-DMAC7.html)
IL (2) IL268732B2 (cg-RX-API-DMAC7.html)
LT (1) LT3583103T (cg-RX-API-DMAC7.html)
MX (2) MX2019009655A (cg-RX-API-DMAC7.html)
PE (2) PE20242300A1 (cg-RX-API-DMAC7.html)
PL (1) PL3583103T3 (cg-RX-API-DMAC7.html)
PT (1) PT3583103T (cg-RX-API-DMAC7.html)
RS (1) RS63162B1 (cg-RX-API-DMAC7.html)
SA (1) SA519402443B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907375VA (cg-RX-API-DMAC7.html)
SI (1) SI3583103T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200121T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018148816A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201906106B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175366A1 (en) 2000-04-14 2003-09-18 Gilles Pauly Plant Extracts and Methods of Treating Skin Therewith
WO2003094946A1 (en) 2002-05-10 2003-11-20 Council Of Scientific And Industrial Research Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
JP2008024670A (ja) 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
WO2008098325A1 (en) * 2007-02-15 2008-08-21 Aché Laboratórios Farmacêuticos S/A Pharmaceutical composition on the basis of stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo
WO2013032308A2 (ko) * 2011-09-02 2013-03-07 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699A (zh) 2011-11-18 2013-05-29 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
WO2016128471A1 (de) * 2015-02-12 2016-08-18 Wilmanowicz Renate Immunologisch aktives phyto-gemisch und seine anwendung bei der prävention und in einem verfahren zur behandlung von effloreszenzen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
IL57433A (en) * 1978-06-03 1982-08-31 Inst Rech Chim Biolog Pharmaceutical compositions containing cyclopentane derivatives
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
US7501222B2 (en) * 2005-06-24 2009-03-10 Dongjin Semichem Co., Ltd. Photoresist monomer polymer thereof and photoresist composition including the same
US8552210B2 (en) * 2006-12-21 2013-10-08 E I Du Pont De Nemours And Company Hydrogenation of catmint oil
BR102017003318A2 (pt) 2017-02-17 2018-10-30 Aché Laboratórios Farmacêuticos S.A. compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175366A1 (en) 2000-04-14 2003-09-18 Gilles Pauly Plant Extracts and Methods of Treating Skin Therewith
WO2003094946A1 (en) 2002-05-10 2003-11-20 Council Of Scientific And Industrial Research Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
JP2008024670A (ja) 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
WO2008098325A1 (en) * 2007-02-15 2008-08-21 Aché Laboratórios Farmacêuticos S/A Pharmaceutical composition on the basis of stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo
JP2010518127A (ja) 2007-02-15 2010-05-27 アシェ ラボラトリオス ファルマセウチコス ソシエダッド アノニマ スタキタルフェタ種(Stachytarphetasp.)に基づく医薬組成物、その取得のための方法及び白斑症を処置するためのその使用
WO2013032308A2 (ko) * 2011-09-02 2013-03-07 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699A (zh) 2011-11-18 2013-05-29 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
WO2016128471A1 (de) * 2015-02-12 2016-08-18 Wilmanowicz Renate Immunologisch aktives phyto-gemisch und seine anwendung bei der prävention und in einem verfahren zur behandlung von effloreszenzen
US20180036360A1 (en) 2015-02-12 2018-02-08 Renate Wilmanowicz Immunologically active phyto-mixture and its use in the prevention and in a method for treatment of efflorescences

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chem.Pharm.Bull. 25(12) 3422-3424(1977) (1977.05.14.) 1부.*
J. Chem. Phys., Vol. 119, No. 23(2003.12.02.) 1부.*
J. Org. Chem., Vol. 37, No. 21, 1972 (1972.03.28.) 1부.*
J. Phys. Chem. B 2004, 108, 4916-4921 (2004.03.23.) 1부.*
Journal of Molecular Structure 875 (2008) 27-31 (2007.04.12.) 1부.*

Also Published As

Publication number Publication date
JP2023061959A (ja) 2023-05-02
CO2019008891A2 (es) 2020-01-17
CN110475768A (zh) 2019-11-19
IL268732B2 (en) 2024-12-01
SMT202200121T1 (it) 2022-07-21
PE20242300A1 (es) 2024-12-11
CL2019002309A1 (es) 2020-05-29
CY1125187T1 (el) 2023-06-09
BR112019017128A2 (pt) 2020-04-14
EP3583103A2 (en) 2019-12-25
IL268732B1 (en) 2024-08-01
AU2018221956A1 (en) 2019-08-29
AU2022201835A1 (en) 2022-04-07
US20200231561A1 (en) 2020-07-23
IL313974A (en) 2024-08-01
JP7349362B2 (ja) 2023-09-22
KR20250145126A (ko) 2025-10-13
BR102017003318A2 (pt) 2018-10-30
ES2909387T3 (es) 2022-05-06
RU2019129095A3 (cg-RX-API-DMAC7.html) 2021-10-27
JP7685540B2 (ja) 2025-05-29
RU2019129095A (ru) 2021-03-17
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
JP2020507607A (ja) 2020-03-12
RS63162B1 (sr) 2022-05-31
DK3583103T3 (da) 2022-03-14
SG11201907375VA (en) 2019-09-27
SA519402443B1 (ar) 2023-02-08
AU2022201835B2 (en) 2024-05-30
PL3583103T3 (pl) 2022-08-01
MX2022012282A (es) 2022-10-27
KR20190121790A (ko) 2019-10-28
WO2018148816A3 (en) 2018-10-18
PT3583103T (pt) 2022-03-25
NZ756074A (en) 2025-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
WO2018148816A4 (en) 2019-01-03
CA3259255A1 (en) 2025-04-04
WO2018148816A2 (en) 2018-08-23
CA3052713A1 (en) 2018-08-23
US12698265B2 (en) 2026-08-04
MX2019009655A (es) 2020-07-24
ZA201906106B (en) 2020-08-26
PE20200449A1 (es) 2020-02-28
ZA202501840B (en) 2025-10-29
SI3583103T1 (sl) 2022-07-29
LT3583103T (lt) 2022-04-25
CN110475768B (zh) 2023-12-01
ECSP19058322A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7685540B2 (ja) 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用
JP2005526053A (ja) 温血動物の免疫、抗炎症性、抗腫瘍性、及びdna修復の工程を促進するための、植物種の水溶性抽出物の生体活性成分の単離、精製、及び構造同定
CN1518454A (zh) 具有抗炎活性和抗动脉粥样硬化活性的藿香提取物以及含有从所述提取物中分离和提纯的椴素的组合物
KR101734093B1 (ko) 알러지 유발 물질을 저감시킨 정제 봉독을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
Kumar et al. Antiproliferative role of Indigofera aspalathoides on 20 methylcholanthrene induced fibrosarcoma in rats
RU2781809C2 (ru) Соединение, способ получения соединений, обогащенный экстракт, активные фракции обогащенного экстракта, способ получения обогащенного экстракта, способ отбора растительной биомассы для получения обогащенного экстракта, композиция и применение для лечения иммунологических нарушений
KR101051076B1 (ko) 개복숭아를 포함하는 알레르기 치료용 조성물 및 이의 제조방법
HK40074103A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders and vitiligo
CN103408528B (zh) 一种色满化合物及其制备方法和应用
HK40011154B (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
US12527832B2 (en) Enriched Withania somnifera based dietary composition and a method thereof
HK40011154A (en) Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders
BR122025011688A2 (pt) Compostos de fórmula (ii), uso de compostos de fórmula (ii), composição farmacêutica, processo para produção de extrato enriquecido com derivados de ipolamida da fórmula (ii), extratos de plantas do gênero stachytarpheta e uso dos extratos de plantas do gênero stachytarpheta
BR112019017128B1 (pt) Processo para produção de extrato enriquecido com derivados de ipolamida
US20110092585A1 (en) Immunomodulatory pharmaceutical composition and a process for preparation thereof
CN120549906A (zh) 杨梅醇作为降血脂药物应用
CN101829145A (zh) 一种麋鹿角活性部位及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000